While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about how all of the major clinical research in the U.S. is in adult stem cells.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Parsing the Debate Over Embryonic Stem Cells
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about how all of the major clinical research in the U.S. is in adult stem cells.
Presenters
Facebook Comments